CD80 and neoplasm: Durvalumab is a humanized IgG1 mAb with high affinity targeting PD-L1 that selectively blocks the binding of PD-L1 to PD-1 and CD-80/B7-1, thus enabling T cells to recognize and kill tumor cells.